DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2017/0029891 A1 SHARP Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2017/0029891 A1 SHARP Et Al US 2017.0029891A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0029891 A1 SHARP et al. (43) Pub. Date: Feb. 2, 2017 (54) BOMARKERS FOR DAGNOSING (60) Provisional application No. 61/584.232, filed on Jan. SCHEMA 7, 2012. (71) Applicant: The Regents of the University of California, Oakland, CA (US) Publication Classification (51) Int. C. (72) Inventors: Frank SHARP, Davis, CA (US); Glen CI2O I/68 (2006.01) C. JICKLING, Sacramento, CA (US) (52) U.S. C. (73) Assignee: The Regents of the University of CPC ....... CI2O 1/6883 (2013.01); C12O 2600/158 California, Oakland, CA (US) (2013.01); C12O 2600/118 (2013.01) (21) Appl. No.: 15/226,844 (57) ABSTRACT (22) Filed: Aug. 2, 2016 The present invention provides methods and compositions for diagnosing and predicting the occurrence of ischemia. Related U.S. Application Data For example, the present invention provides methods and (63) Continuation of application No. 14/370.709, filed on compositions for diagnosing and predicting the risk and Jul. 3, 2014, now Pat. No. 9,410,204, filed as appli cause of transient neurological events (TNE) as ischemic or cation No. PCT/US2013/020240 on Jan. 4, 2013. non-ischemic. Patent Application Publication Feb. 2, 2017. Sheet 1 of 3 US 2017/0029891 A1 TA (n=263 WS schemic Stroke (n=94) VRF Contro ra.) vs WRF Control (n=44) Fig. 1 A. Derivation Cross-Walidation 26 Gene 10-fold leave-one-out DA Prediction Model TA-DW+f Minor Stroke (n=17) Fia. 1 B. Validation g Nonischemic TNE {n=13) Fig. 1 C. Prediction Unclear TNE (n=14) Fig. 1A-C Patent Application Publication Feb. 2, 2017. Sheet 2 of 3 US 2017/0029891 A1 lschemic Stroke TA CD4 2% Monocytes 22% Granulocytes 64% Granulocytes 38% Fig. 2 Patent Application Publication Feb. 2, 2017. Sheet 3 of 3 US 2017/0029891 A1 --Control Probability -Crischemia Probability s s s 2. 25 so Fig. 3B ar ischemic "“” Stroke 3.25v.au :---------------------------------------------------------------------------------------------c. goo &x3xxxx8 s 2. 3. a. ESO Fig. 3C 1.00 is 0.7s 3 Control Q.50 : - .2: US 2017/0029891 A1 Feb. 2, 2017 BIOMARKERS FOR DIAGNOSING (Rothwell, et al., Lancet. (2007) 370:1432-1442). Addition ISCHEMA ally, identifying nonischemic TNE (which have a very low risk of stroke) will improve risk stratification and use of CROSS-REFERENCE TO RELATED health care resources. Thus, improved methods to distin APPLICATIONS guish ischemic from nonischemic causes of TNE are needed. 0001. This application is a continuation of U.S. applica 0006 Previous studies have demonstrated an immune tion Ser. No. 14/370,709, filed on Jul. 3, 2014, issued as U.S. response in patients with stroke by evaluating leukocyte Pat. No. 9,410,204 on Aug. 9, 2016, which is a U.S. national RNA expression using whole genome microarrays (Barr, et phase under 35 U.S.C. S371 of International Application No. al., Neurology. (2010) 75:1009-1014; Jickling, et al. Ann PCT/US2013/020240, filed on Jan. 4, 2013, which claims Neurol. (2010) 68:681-692; and Stamova, et al., Stroke. the benefit under 35 U.S.C. S 119(e) of U.S. Provisional (2010) 41:2171-2177). However, the distinction between Application No. 61/584.232, filed on Jan. 7, 2012, which are immune response to cerebral ischemia and cerebral infarc hereby incorporated herein by reference in their entireties tion was unclear. We report herein the pathways associated for all purposes. with the peripheral immune response to cerebral ischemia, which has clinical utility to identify ischemic causes of TNE. STATEMENT OF GOVERNMENTAL SUPPORT SUMMARY OF THE INVENTION 0002 This invention was made with government support under Grant No. NS056302 awarded by the National Insti 0007. The present invention provides biomarkers useful tutes of Health. The government has certain rights in the for diagnosing the occurrence or risk of ischemia, particu invention. larly transient cerebral ischemia, and for differentiating a transient neurological event as ischemic or non-ischemic. FIELD OF THE INVENTION Accordingly, in one aspect, the invention provides methods for diagnosing transient cerebral ischemia or a predisposi 0003. The present invention provides methods and com tion for experiencing transient cerebral ischemia. In some positions for diagnosing and predicting the occurrence of embodiments, the methods comprise: determining a level of ischemia. For example, the present invention provides meth expression of a plurality of ischemia-associated biomarkers ods and compositions for diagnosing and predicting the risk in a biological sample from a patient, wherein an increase or and cause of transient neurological events (TNE) as isch decrease of the level of expression compared to a control is emic or non-ischemic. correlative with or indicates that the patient has suffered or is at risk of experiencing transient cerebral ischemia, BACKGROUND OF THE INVENTION wherein the plurality of ischemia-associated biomarkers is 0004 Systemic inflammation is linked to ischemic stroke selected from the biomarkers set forth in Tables 3 and 5, and transient ischemic attack (TIA). Cerebral ischemia pro thereby diagnosing transient cerebral ischemia or a predis duces many endogenous ligands and cytokines that elicit an position for experiencing transient cerebral ischemia. immune response (Arumugam, et al., Shock. (2009) 32:4- 10008. In another aspect, the invention provides methods 16). Leukocytes, including neutrophils and monocytes, are for diagnosing and/or differentiating a transient neurological activated and recruited to initiate processes of containment, event (TNE) as ischemic or non-ischemic. In some embodi removal, and repair. We have previously demonstrated in a ments, the methods comprise: determining a level of expres rat model of TIA that a peripheral immune response occurs Sion of a plurality of ischemia-associated biomarkers in a to transient brain ischemia with similarities to that observed biological sample from a patient, wherein an increase or in experimental brain infarction (Zhan, et al., J. Cereb Blood decrease of the level of expression compared to a control is Flow Metab. (2010) 30:110-118; Zhan, et al., Brain Res. correlative with or indicates that the patient has suffered or (2008) 1234:183-197). This suggests that aspects of the is at risk of experiencing transient cerebral ischemia, immune response to cerebral ischemia in TIA and stroke are wherein the plurality of ischemia-associated biomarkers is common and may be useful in identifying ischemic events. selected from the biomarkers set forth in Tables 3 and 5, 0005. In clinical practice, deciphering whether a transient thereby diagnosing a transient neurological event (TNE) as neurological event (TNE) is of ischemic or nonischemic ischemic or non-ischemic. etiology is often difficult. Many common neurological con 0009. In a related aspect, the invention provides methods ditions mimic the symptoms of TIA, including migraine, for identifying the occurrence or a predisposition for expe seizure, and syncope. The transient nature of TIA adds to the riencing ischemia. In some embodiments, the methods com diagnostic challenge as objective deficits generally resolve prise: determining a level of expression of a plurality of by the time of presentation and assessment of symptoms is ischemia-associated biomarkers in a biological sample from reliant on patient recall and physician interpretation. Current a patient, wherein an increase or decrease of the level of diagnostic tests including neuroimaging, electrocardiogram, expression compared to a control is correlative with or and electroencephalogram are frequently unremarkable, indicates that the patient has suffered or is at risk of leaving the cause of a TNE unclear. As a result, TIA is experiencing ischemia, wherein the plurality of ischemia estimated to be incorrectly diagnosed in as many as 50% of associated biomarkers is selected from the biomarkers set cases (Ferro, et al., Stroke. (1996) 27:2225-2229; Kraai forth in Tables 3 and 5, thereby identifying the occurrence or jeveld, et al., Stroke. (1984) 15:723-725; Castle, et al., a predisposition for experiencing ischemia. In some embodi Stroke. (2010) 41: 1367-1370; Bos, et al., JAMA. (2007) ments, the ischemia is selected from the group consisting of 298:2877-2885; and Johnston S. C.JAMA. (2007)298:2912 cerebral ischemia, myocardial ischemia and pulmonary isch 2913). However, correctly identifying ischemic TNE is emia. critical as the risk for stroke is high in TIA and can be 10010 With respect to embodiments of the methods, in reduced by early initiation of stroke prevention therapy Some embodiments, an increased expression level of one or US 2017/0029891 A1 Feb. 2, 2017 more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or all) decreased expression level of one or more (e.g., 2, 3, 4, 5, ischemia-associated biomarkers selected from the group 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30 or all) consisting of UBE2J1, ELAVL3, FCGR2B, BLVRA, ischemia-associated biomarkers selected from the group JMJD6, DDAH2, PTRH2, CARD16, CAV 1, ZNF608, consisting of CARD16, IRF7, TLR6, NMU, C13orf16, NDUFB3, SLC22A4, PCMT1, CACNA1A, CASP1 and TAPBP. BTC, ZBP1, HSPA6, TWIST1, PLSCR1, LOC100129105 indicates that the patient has suffered or is SAMD9L, OSTCL, C90rf66, GYPA, ADM, ANKRD22, at risk of experiencing ischemia. In some embodiments, an SHOX, ZNF354A, SRGAP1, GRM5, BAGE, XRCC4, increased expression level of one or more (e.g., 2, 3, 4, 5, 6, SLC37A3, OVOL2, LIFR, RASAL2, hCG 1749898, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40 or all) IQGAP3, HS3ST3A1, NPR3, SIX3 and HCN1 indicates ischemia-associated biomarkers selected from the group that the patient has not suffered or is not at risk of experi consisting of AIM2, C14orf101, DNAH17, UBE2J1, encing ischemia. In some embodiments, a decreased expres LOC203274 PGS1, ZEB2.
Load more

Recommended publications
  • To Study Mutant P53 Gain of Function, Various Tumor-Derived P53 Mutants
    Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science By Shama K Khokhar M.Sc., Bilaspur University, 2004 B.Sc., Bhopal University, 2002 2007 1 COPYRIGHT SHAMA K KHOKHAR 2007 2 WRIGHT STATE UNIVERSITY SCHOOL OF GRADUATE STUDIES Date of Defense: 12-03-07 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY SHAMA KHAN KHOKHAR ENTITLED Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science Madhavi P. Kadakia, Ph.D. Thesis Director Daniel Organisciak , Ph.D. Department Chair Committee on Final Examination Madhavi P. Kadakia, Ph.D. Steven J. Berberich, Ph.D. Michael Leffak, Ph.D. Joseph F. Thomas, Jr., Ph.D. Dean, School of Graduate Studies 3 Abstract Khokhar, Shama K. M.S., Department of Biochemistry and Molecular Biology, Wright State University, 2007 Differential effect of TAp63γ mutants on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. p63, a member of the p53 gene family, known to play a role in development, has more recently also been implicated in cancer progression. Mice lacking p63 exhibit severe developmental defects such as limb truncations, abnormal skin, and absence of hair follicles, teeth, and mammary glands. Germline missense mutations of p63 have been shown to be responsible for several human developmental syndromes including SHFM, EEC and ADULT syndromes and are associated with anomalies in the development of organs of epithelial origin.
    [Show full text]
  • Drosophila and Human Transcriptomic Data Mining Provides Evidence for Therapeutic
    Drosophila and human transcriptomic data mining provides evidence for therapeutic mechanism of pentylenetetrazole in Down syndrome Author Abhay Sharma Institute of Genomics and Integrative Biology Council of Scientific and Industrial Research Delhi University Campus, Mall Road Delhi 110007, India Tel: +91-11-27666156, Fax: +91-11-27662407 Email: [email protected] Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 Running head: Pentylenetetrazole mechanism in Down syndrome 1 Abstract Pentylenetetrazole (PTZ) has recently been found to ameliorate cognitive impairment in rodent models of Down syndrome (DS). The mechanism underlying PTZ’s therapeutic effect is however not clear. Microarray profiling has previously reported differential expression of genes in DS. No mammalian transcriptomic data on PTZ treatment however exists. Nevertheless, a Drosophila model inspired by rodent models of PTZ induced kindling plasticity has recently been described. Microarray profiling has shown PTZ’s downregulatory effect on gene expression in fly heads. In a comparative transcriptomics approach, I have analyzed the available microarray data in order to identify potential mechanism of PTZ action in DS. I find that transcriptomic correlates of chronic PTZ in Drosophila and DS counteract each other. A significant enrichment is observed between PTZ downregulated and DS upregulated genes, and a significant depletion between PTZ downregulated and DS dowwnregulated genes. Further, the common genes in PTZ Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 downregulated and DS upregulated sets show enrichment for MAP kinase pathway. My analysis suggests that downregulation of MAP kinase pathway may mediate therapeutic effect of PTZ in DS. Existing evidence implicating MAP kinase pathway in DS supports this observation.
    [Show full text]
  • Rabbit Anti-GRLF1/FITC Conjugated Antibody
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-GRLF1/FITC Conjugated antibody SL16321R-FITC Product Name: Anti-GRLF1/FITC Chinese Name: FITC标记的糖皮质激素受体DNA结合因子1抗体 ARHGAP35; GAP associated protein p190; Glucocorticoid receptor DNA binding factor 1; Glucocorticoid receptor DNA-binding factor 1; Glucocorticoid receptor repression factor 1; Glucocorticoid receptor repression factor 1; GRF 1; GRF-1; GRF1; Alias: GRLF 1; GRLF1; GRLF1_HUMAN; KIAA1722; MGC10745; p190 A; p190-A; P190A; P190A, rat, homolog of; p190ARhoGAP; p190RhoGAP; Rho GAP p190A; Rho GAP p190A; Rho GTPase-activating protein 35. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Cow,Horse,Rabbit,Sheep, ICC=1:50-200IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 170kDa Form: Lyophilized or Liquid Concentration: 1mg/ml immunogen: KLHwww.sunlongbiotech.com conjugated synthetic peptide derived from human GRLF1 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. background: The human glucocorticoid receptor DNA binding factor, which associates with the Product Detail: promoter region of the glucocorticoid receptor gene (hGR gene), is a repressor of glucocorticoid receptor transcription.
    [Show full text]
  • The Potential Role of Environmental Exposures and Genomic Signaling
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 11-14-2011 The otP ential Role of Environmental Exposures and Genomic Signaling in Development of Central Nervous System Tumors Brian W. Kunkle Florida International University, [email protected] DOI: 10.25148/etd.FI11120809 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Recommended Citation Kunkle, Brian W., "The otP ential Role of Environmental Exposures and Genomic Signaling in Development of Central Nervous System Tumors" (2011). FIU Electronic Theses and Dissertations. 524. https://digitalcommons.fiu.edu/etd/524 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida THE POTENTIAL ROLE OF ENVIRONMENTAL EXPOSURES AND GENOMIC SIGNALING IN DEVELOPMENT OF CENTRAL NERVOUS SYSTEM TUMORS A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in PUBLIC HEALTH by Brian William Kunkle 2011 To: Interim Dean Michelle Cicazzo Robert Stempel College of Public Health and Social Work This dissertation written by Brian William Kunkle, and entitled The Potential Role of Environmental Exposures and Genomic Signaling in Development of Central Nervous System Tumors, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. ____________________________________ Changwon Yoo ____________________________________ Quentin Felty ____________________________________ Nasar Ahmed ____________________________________ Deodutta Roy, Major Professor Date of Defense: November 14, 2011 The dissertation of Brian William Kunkle is approved.
    [Show full text]
  • Differences in Gene Expression Profiles and Carcinogenesis Pathways Involved in Cisplatin Resistance of Four Types of Cancer
    596 ONCOLOGY REPORTS 30: 596-614, 2013 Differences in gene expression profiles and carcinogenesis pathways involved in cisplatin resistance of four types of cancer YONG YANG1,2, HUI LI1,2, SHENGCAI HOU1,2, BIN HU1,2, JIE LIU1,3 and JUN WANG1,3 1Beijing Key Laboratory of Respiratory and Pulmonary Circulation, Capital Medical University, Beijing 100069; 2Department of Thoracic Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020; 3Department of Physiology, Capital Medical University, Beijing 100069, P.R. China Received December 23, 2012; Accepted March 4, 2013 DOI: 10.3892/or.2013.2514 Abstract. Cisplatin-based chemotherapy is the standard Introduction therapy used for the treatment of several types of cancer. However, its efficacy is largely limited by the acquired drug Cisplatin is primarily effective through DNA damage and is resistance. To date, little is known about the RNA expression widely used for the treatment of several types of cancer, such changes in cisplatin-resistant cancers. Identification of the as testicular, lung and ovarian cancer. However, the ability RNAs related to cisplatin resistance may provide specific of cancer cells to become resistant to cisplatin remains a insight into cancer therapy. In the present study, expression significant impediment to successful chemotherapy. Although profiling of 7 cancer cell lines was performed using oligo- previous studies have identified numerous mechanisms in nucleotide microarray analysis data obtained from the GEO cisplatin resistance, it remains a major problem that severely database. Bioinformatic analyses such as the Gene Ontology limits the usefulness of this chemotherapeutic agent. Therefore, (GO) and KEGG pathway were used to identify genes and it is crucial to examine more elaborate mechanisms of cisplatin pathways specifically associated with cisplatin resistance.
    [Show full text]
  • WO 2012/054896 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number ι (43) International Publication Date ¾ ί t 2 6 April 2012 (26.04.2012) WO 2012/054896 Al (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, C12N 5/00 (2006.01) C12N 15/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, C12N 5/02 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (21) International Application Number: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, PCT/US201 1/057387 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (22) International Filing Date: NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, 2 1 October 201 1 (21 .10.201 1) RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (25) Filing Language: English ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/406,064 22 October 2010 (22.10.2010) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 61/415,244 18 November 2010 (18.1 1.2010) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, (71) Applicant (for all designated States except US): BIO- DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, TIME INC.
    [Show full text]
  • GRLF1 Antibody Product Type
    PRODUCT INFORMATION Product name：GRLF1 antibody Product type： Primary antibodies Description： Mouse monoclonal to GRLF1 Immunogen：1 synthetic peptide (human) conjugated to KLH Reacts with： Hu, Ms Tested applications：ELISA, WB & IF GENE INFORMATION Gene Symbol：GRLF1 Gene Name：Rho GTPase activating protein 35 Ensembl ID：ENSG00000160007 Entrez GeneID：2909 GenBank Accession number：M73077 Swiss­Prot：Q9NRY4 Molecular weight：170.5kDa Function：Represses transcription of the glucocorticoid receptor by binding to the cis­acting regulatory sequence 5'­GAGAAAAGAAACTGGAGAAACTC­3'. May participate in the regulation of retinal development and degeneration. May transduce signals from p21­ras to the nucleus, acting via the ras GTPase­activating protein (GAP). May also act as a tumor suppressor. Expected subcellular localization：Cytoplasm. Nucleus. Summary：The human glucocorticoid receptor DNA binding factor, which associates with the promoter region of the glucocorticoid receptor gene (hGR gene), is a repressor of glucocorticoid receptor transcription. The amino acid sequence deduced from the cDNA sequences show the presence of three sequence motifs characteristic of a zinc finger and one motif suggestive of a leucine zipper in which 1 cysteine is found instead of all leucines. The GRLF1 enhances the homologous down­regulation of wild­type hGR gene expression. Biochemical analysis suggests that GRLF1 interaction is sequence specific and that transcriptional efficacy of GRLF1 is regulated through its interaction with specific sequence motif. The level of expression is regulated by glucocorticoids. [provided by RefSeq, Jul 2008] APPLICATION NOTE Recommended dilution： • ELISA: Antibody specificity was verified by direct ELISA against the 1 immunogen peptide. A titer of 8000 has been determined. Appropriate specificity controls were run.
    [Show full text]
  • Differential Effects of Mutant Tap63î³ on Transactivation of P53 And/Or P63
    Wright State University CORE Scholar Browse all Theses and Dissertations Theses and Dissertations 2007 Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression Shama Khan Khokhar Wright State University Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all Part of the Molecular Biology Commons Repository Citation Khokhar, Shama Khan, "Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression" (2007). Browse all Theses and Dissertations. 207. https://corescholar.libraries.wright.edu/etd_all/207 This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE Scholar. For more information, please contact [email protected]. Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science By Shama K Khokhar M.Sc., Bilaspur University, 2004 B.Sc., Bhopal University, 2002 2007 1 COPYRIGHT SHAMA K KHOKHAR 2007 2 WRIGHT STATE UNIVERSITY SCHOOL OF GRADUATE STUDIES Date of Defense: 12-03-07 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY SHAMA KHAN KHOKHAR ENTITLED Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science Madhavi P.
    [Show full text]
  • Supplemental Solier
    Supplementary Figure 1. Importance of Exon numbers for transcript downregulation by CPT Numbers of down-regulated genes for four groups of comparable size genes, differing only by the number of exons. Supplementary Figure 2. CPT up-regulates the p53 signaling pathway genes A, List of the GO categories for the up-regulated genes in CPT-treated HCT116 cells (p<0.05). In bold: GO category also present for the genes that are up-regulated in CPT- treated MCF7 cells. B, List of the up-regulated genes in both CPT-treated HCT116 cells and CPT-treated MCF7 cells (CPT 4 h). C, RT-PCR showing the effect of CPT on JUN and H2AFJ transcripts. Control cells were exposed to DMSO. β2 microglobulin (β2) mRNA was used as control. Supplementary Figure 3. Down-regulation of RNA degradation-related genes after CPT treatment A, “RNA degradation” pathway from KEGG. The genes with “red stars” were down- regulated genes after CPT treatment. B, Affy Exon array data for the “CNOT” genes. The log2 difference for the “CNOT” genes expression depending on CPT treatment was normalized to the untreated controls. C, RT-PCR showing the effect of CPT on “CNOT” genes down-regulation. HCT116 cells were treated with CPT (10 µM, 20 h) and CNOT6L, CNOT2, CNOT4 and CNOT6 mRNA were analysed by RT-PCR. Control cells were exposed to DMSO. β2 microglobulin (β2) mRNA was used as control. D, CNOT6L down-regulation after CPT treatment. CNOT6L transcript was analysed by Q- PCR. Supplementary Figure 4. Down-regulation of ubiquitin-related genes after CPT treatment A, “Ubiquitin-mediated proteolysis” pathway from KEGG.
    [Show full text]
  • Comparative Gene Expression Analysis to Identify Common Factors in Multiple Cancers
    COMPARATIVE GENE EXPRESSION ANALYSIS TO IDENTIFY COMMON FACTORS IN MULTIPLE CANCERS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Leszek A. Rybaczyk, B.A. ***** The Ohio State University 2008 Dissertation Committee: Professor Kun Huang, Adviser Professor Jeffery Kuret Approved by Professor Randy Nelson Professor Daniel Janies ------------------------------------------- Adviser Integrated Biomedical Science Graduate Program ABSTRACT Most current cancer research is focused on tissue-specific genetic mutations. Familial inheritance (e.g., APC in colon cancer), genetic mutation (e.g., p53), and overexpression of growth receptors (e.g., Her2-neu in breast cancer) can potentially lead to aberrant replication of a cell. Studies of these changes provide tremendous information about tissue-specific effects but are less informative about common changes that occur in multiple tissues. The similarity in the behavior of cancers from different organ systems and species suggests that a pervasive mechanism drives carcinogenesis, regardless of the specific tissue or species. In order to detect this mechanism, I applied three tiers of analysis at different levels: hypothesis testing on individual pathways to identify significant expression changes within each dataset, intersection of results between different datasets to find common themes across experiments, and Pearson correlations between individual genes to identify correlated genes within each dataset. By comparing a variety of cancers from different tissues and species, I was able to separate tissue and species specific effects from cancer specific effects. I found that downregulation of Monoamine Oxidase A is an indicator of this pervasive mechanism and can potentially be used to detect pathways and functions related to the initiation, promotion, and progression of cancer.
    [Show full text]
  • Transcriptomic Analysis of Patients with Tetralogy of Fallot Reveals the Effect of Chronic Hypoxia on Myocardial Gene Expression
    Ghorbel et al Congenital Heart Disease Transcriptomic analysis of patients with tetralogy of Fallot reveals the effect of chronic hypoxia on myocardial gene expression Mohamed T. Ghorbel, PhD, Myriam Cherif, PhD, Emma Jenkins, PhD, Amir Mokhtari, MRCS, Damien Kenny, MRCPCH, Gianni D. Angelini, FRCS, and Massimo Caputo, MD Objectives: In cyanotic patients undergoing repair of heart defects, chronic hypoxia is thought to lead to greater susceptibility to ischemia and reoxygenation injury. We sought to find an explanation to such a hypothesis by investigating the cardiac gene expression in patients with tetralogy of Fallot undergoing cardiac surgery. CHD Methods: The myocardial gene profile was investigated in right ventricular biopsy specimens obtained from 20 patients with a diagnosis of cyanotic (n ¼ 11) or acyanotic (n ¼ 9) tetralogy of Fallot undergoing surgical repair. Oligonucleotide microarray analyses were performed on the samples, and the array results were validated with Western blotting and enzyme-linked immunosorbent assay. Results: Data revealed 795 differentially expressed genes in cyanotic versus acyanotic hearts, with 198 upregu- lated and 597 downregulated. Growth/morphogenesis, remodeling, and apoptosis emerged as dominant func- tional themes for the upregulated genes and included the apoptotic gene TRAIL (tumor necrosis factor–related apoptosis-inducing ligand), the remodeling factor OPN (osteopontin), and the mitochondrial function gene COX11 (cytochrome-c oxidase 11). In contrast, transcription, mitogen-activated protein kinase signaling, and contractile machinery were the dominant functional classes for the downregulated genes, which included the calcium-handling gene NCX1 (sodium-calcium exchanger). Protein levels of COX11, NCX1, OPN, and LYZ (ly- sozyme) in the myocardium followed the same pattern obtained by means of transcriptomics.
    [Show full text]
  • Supplementary Data
    SUPPLEMENTAL INFORMATION A study restricted to chemokine receptors as well as a genome-wide transcript analysis uncovered CXCR4 as preferentially expressed in Ewing's sarcoma (Ewing's sarcoma) cells of metastatic origin (Figure 4). Transcriptome analyses showed that in addition to CXCR4, genes known to support cell motility and invasion topped the list of genes preferentially expressed in metastasis-derived cells (Figure 4D). These included kynurenine 3-monooxygenase (KMO), galectin-1 (LGALS1), gastrin-releasing peptide (GRP), procollagen C-endopeptidase enhancer (PCOLCE), and ephrin receptor B (EPHB3). KMO, a key enzyme of tryptophan catabolism, has not been linked to metastasis. Tryptophan and its catabolites, however, are involved in immune evasion by tumors, a process that can assist in tumor progression and metastasis (1). LGALS1, GRP, PCOLCE and EPHB3 have been linked to tumor progression and metastasis of several cancers (2-4). Top genes preferentially expressed in L-EDCL included genes that suppress cell motility and/or potentiate cell adhesion such as plakophilin 1 (PKP1), neuropeptide Y (NPY), or the metastasis suppressor TXNIP (5-7) (Figure 4D). Overall, L-EDCL were enriched in gene sets geared at optimizing nutrient transport and usage (Figure 4D; Supplementary Table 3), a state that may support the early stages of tumor growth. Once tumor growth outpaces nutrient and oxygen supplies, gene expression programs are usually switched to hypoxic response and neoangiogenesis, which ultimately lead to tumor egress and metastasis. Accordingly, gene sets involved in extracellular matrix remodeling, MAPK signaling, and response to hypoxia were up-regulated in M-EDCL (Figure 4D; Supplementary Table 4), consistent with their association to metastasis in other cancers (8, 9).
    [Show full text]